Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma
1 other identifier
observational
300
1 country
1
Brief Summary
The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020. The clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 30, 2022
CompletedStudy Start
First participant enrolled
June 30, 2022
CompletedFirst Posted
Study publicly available on registry
July 11, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2022
CompletedJuly 12, 2022
June 1, 2022
20 days
June 30, 2022
July 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline OGTT（oral glucose tolerance test）results to 6-12 months after surgery
OGTT results （including fasting blood glucose in the text, blood glucose results at 2 hours after oral administration of 75g glucose）at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia
Baseline, 6-12 months after surgery
Secondary Outcomes (3)
random blood glucose results
baseline, 6-12 months after surgery
HbA1c
baseline, 6-12 months after surgery
fasting blood glucose
baseline, 6-12 months after surgery
Study Arms (2)
patients with dysglycemia
Patients with dysglycemia in the included subjects with pheochromocytoma and paraganglioma
patients without dysglycemia
Patients without dysglycemia in the included subjects with pheochromocytoma and paraganglioma
Interventions
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
Eligibility Criteria
This retrospective cohort study will include all consecutive adult patients who underwent surgery for pheochromocytomas and paragangliomas from January 2018 to June 2020.
You may qualify if:
- age ≥18 years old
- patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(PPGLs)
You may not qualify if:
- recurrent PPGLs
- patients who required steroids after adrenalectomy
- patients with inadequate clinical records were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xian-Liang Zhou
Beijing, Beijing Municipality, 100037, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xian-Liang Zhou
National Center for Cardiovascular Diseases; Fuwai Hospital, Chinese Academy of Medical Sciences
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2022
First Posted
July 11, 2022
Study Start
June 30, 2022
Primary Completion
July 20, 2022
Study Completion
July 20, 2022
Last Updated
July 12, 2022
Record last verified: 2022-06